• 한방안이비인후피부과학회지
• /
• 제31권1호
• /
• pp.71-80
• /
• 2018

Objectives : The purpose of this study is to evaluate the clinical aspects of patients with Soyangin vitiligo. Methods : This clinical investigation was made with 148 Soyangin Vitiligo patients who visited Haneulmaeum Oriental Medicine Clinic (Incheon) from July 1st 2007 to June 30th 2017. Results & Conclusions : 1. There were 73 males(49.3%) and 75 females(50.7%). 2. The Mean age at the first visit was 36.1 years(male: 36.4, female: 35.8). 3. The Mean age of onset was 27.9 years(male: 28.6, female: 27.4). 4. The mean duration of the disease was 8.0 years(male: 7.8, female: 8.3). 5. Of the 148 patients, 41(27.7%) had the symmetric lesions and 107(72.3%) had the asymmetric vitiligo lesions. Of the patients with asymmetric vitiligo lesions, 46(31.1%) had the localized lesions and 26(17.6%) had the segmental lesions and 35(24.3%) had the multiple lesions. 6. The most common site of initial involvement of the vitiligo was the face (39.2%). 7. The most common site of the vitiligo lesions was the face(49.3%). 8. Familial history was obtained in 12 patients(8.1%). 9. There was no known precipitating factor in most cases(89.4%). 10. Thyroid disease was the most common associated disease. 11. The progression of vitiligo was present in 92 patients(62.2%).

• Clinical and Experimental Pediatrics
• /
• 제49권11호
• /
• pp.1211-1215
• /
• 2006

목 적 : 본 연구는 소아 동종 조혈모세포이식 후에 갑상선 기능의 단기간 변화와 갑상선기능이상의 빈도와 위험인자를 분석하고자 하였다. 방 법 : 2004년 1월부터 2006년 2월까지 가톨릭대학교 성모병원 소아과, 조혈모세포이식센터에서 동종 조혈모세포이식을 시행한 80명의 환자를 대상으로 연구를 하였다. 조혈모세포이식 전과 이식 후 1개월, 6개월, 12개월에 환자들의 혈청에서 TSH, T4, T3를 측정하였다. 결 과 : 조혈모세포이식을 하고 1개월 후의 갑상선 기능은 통계적으로 유의한 감소를 보이고 있었다(P<0.001). 1개월 후 갑상선 기능이상의 빈도는 80명중 43명(54%)에서 보였으며 이들 중 31명(39%)은 ETS를 보이고 있었다. 이식 후 일년 이내 갑상선 기능은 대부분 정상으로 회복되었다. 단변량 분석에 의하면 악성 질환인 경우(P=0.04)와 2도 이상의 급성 이식편대 숙주병(P=0.01)이 ETS의 위험인자였으나(P=0.04), 다변량 분석에 의하면 ETS 발생에 독립적인 위험인자는 찾을 수 없었다(P=0.19, 0.06). 결 론 : 조혈모세포이식 후 갑상선 기능이상은 초기에 높은 빈도로 발생함을 알 수 있었다. 따라서 이식 후에는 갑상선 기능의 지속적인 추적검사가 필요하다.

• 대한유전성대사질환학회지
• /
• 제13권2호
• /
• pp.120-125
• /
• 2013

Purpose: McCune-Albright syndrome (MAS) is caused by activating mutations in the GNAS gene, resulting in peripheral precocious puberty, caf$\acute{e}$-au-lait spots, and polyostotic fibrous dysplasia (POFD). The aim of the present study was to describe the diverse clinical and endocrine characteristics of patients with MAS. Methods: Seven patients with MAS were included in this study and medical charts were reviewed retrospectively for following parameters: patient's sex and age at diagnosis, POFD, ovarian cysts, and precocious puberty. Results: The mean age at diagnosis was $5.8{\pm}4.2$ years. One patient was male (14%) and the other six patients were female (86%). Peripheral precocious puberty was associated with 6 patients (86%). Five patients manifested premature menarche as early as 2 to 5 years of age. Letrozole was administered to 4 patients, tamoxifen to one patient and GnRH agonist to one patient. Five females developed ovarian cysts. Thyroid function tests were performed in all patients and one patient showed hyperthyroidism (14%) and has been treated with methimazole. One patient presented with pseudohypoparathyroisdism, phosphaturia, calciuria suggesting hypophosphatemic rickets. Six patients (86%) revealed POFD. One patient had symptoms of optic nerve compression and secondary esotropia and 2 patients had bone pain. Conclusion: This study described clinical characteristics and endocrine complications of patients with MAS. Careful physical examinations with history taking and serial endocrine function tests should be needed to detect complications such as endocrinologic hyperfunction and POFD.

• Journal of Yeungnam Medical Science
• /
• 제31권2호
• /
• pp.103-108
• /
• 2014

Thyroglossal duct cyst (TGDC) carcinoma generally shows a favorable prognosis. If metastasis is present latently, it may not threaten the patient's life immediately. It has been shown, however, that larger than 1 cm papillary carcinoma (PC), level VI metastasis to the lymph node (LN), which is the nearest to the thyroid, independently predicts a worse prognosis. In the case presented herein, a 61-year-old female patient was diagnosed with an about 3 cm PC in the TGDC, particularly the columnar variant subtype, one of the aggressive variants. She had occult papillary thyroid microcarcinoma, but no LN metastasis. Even though she underwent the Sistrunk procedure and total thyroidectomy with central compartment neck dissection followed by high-dose radioactive iodine remnant ablation, however, the cancer cells spread to level IV neck LN, and finally to the lung. Therefore, when a patient is diagnosed with an aggressive histologic variant of PC in the TGDC, even without LN metastasis, the invasive surgical approach and close postoperative surveillance are necessary, with consideration of the risk of disease progression. Therefore, if it is possible to stratify the risk for patients, higher-risk patients can be offered a more invasive therapeutic approach.

• Clinical and Experimental Pediatrics
• /
• 제53권2호
• /
• pp.158-162
• /
• 2010

목 적 : 터너증후군은 45,X의 전형적인 핵형 이외에도 다양한 정도의 X 염색체의 이상을 가진 질환으로 신장, 심혈관 기형, 갑상샘질환 및 청력이상을 동반하는 빈도가 많다. 본 연구에서는 핵형에 따른 동반질환의 발생빈도와 양상을 조사하였다. 방 법 : 1998년 1월부터 2007년 12월까지 호남지역 4개 병원에서 염색체검사상 터너증후군으로 확진된 90명의 의무기록을 후향적으로 분석하였다. 이들의 핵형을 45,X 군, 모자이시즘군, 구조적 이상군으로 분류하고 신장 및 심장초음파, 갑상샘기능검사, 청력검사 등을 통하여 동반질환의 발생빈도를 조사하였다. 결 과 : 45,X 군은 47.8%, 모자이시즘군은 34.4%, 구조적 이상군은 17.8%의 분포를 보였다. 신장, 심혈관 기형, 갑상샘질환, 청력이상은 각각 순서대로 4.4%, 10.0%, 11.1%, 5.6%의 빈도를 보였다. 45,X 군은 신장 기형이 7.0%, 심혈관 기형이 18.6% 갑상샘 질환이 9.3%, 청력이상이 11.6%에서 나타났다. 모자이시즘군은 신장기형이 3.2%, 갑상샘 질환이 12.9%의 발생율을 보였고 심혈관 기형과 청력이상이 있는 환자는 없었다. 구조적 이상군은 심혈관 기형이 6.3%, 갑상샘질환이 12.5%에서 나타났다. 45,X 군에서는 심혈관 질환의 발생율이 다른 두군에 비하여 통계적으로 유의하게 높았다(P =0.025). 결 론 : 터너증후군에서 핵형별로 동반질환의 분포가 다른 양상을 보였으며 적절한 선별검사를 통해 질환을 조기 진단하여 적절한 관리가 필요하리라 생각된다.

• Journal of Chest Surgery
• /
• 제24권1호
• /
• pp.48-53
• /
• 1991

This report documents the clinical k pathologic features of 33 patients treated for thymoma for 11 years & 6 months between September 1977 and February 1989. At the Thoracic & Cardiovascular Surgery, Yonsei University, College of Medicine of the group, 31 patients treated with surgery were examined for the result of operation & prognosis. Mean age was 50 years. Thirteen were female and twenty were male. Dyspnea on exertion and chest discomfort were common in the patients without myasthenia gravis. Fourteen patients[42.6%] had myasthenia gravis and one patient had autoimmune thyroid disease. Four patients[12.1%] presented without symptoms attributable to their thymoma. Histologic review disclosed 12[36.4%] epithelial thymoma, 10[30.3%] mixed lymphoepithelial, 9[27.3%] lymphocytic, 1[3.0%] spindle cell and 1[3.0%] unknown cell thymoma. They were classified according to Masaoka`s clinical staging criteria; by these criteria, 8 patients were stage I, 5 patients were stage II, 15 patients were stage III and 3 patients were stage IV. Total excision of mass was possible in 20 patients. Partial excision of mass in 4 patients and biopsy in 7 patients were carried out during the operation. There was only one operation mortality. Follow-up was possible in 26 patients and follow-up ranged from 4 months to 10.5 years[mean 28.9 months]. One-year survival rates were 77.8% and eight patients expired during follow-up period. Eleven[78.6%] patients with myasthenia gravis were improved after the operation. This observation suggests that the most significant factor determining the survival is whether or not total surgical excision had been performed.

• Journal of Endocrine Surgery
• /
• 제18권4호
• /
• pp.236-239
• /
• 2018

Secondary hyperparathyroidism (SHPTH) occurs commonly in patients with end-stage renal disease (ESRD). Uncontrolled SHPTH is associated with complications of calcium deposition including calciphylaxis and elevated rates of cardiovascular morbidity. Current treatment recommendations for medically refractory disease include total parathyroidectomy, often with autotransplantation (TPTH+AT) of minced parathyroid gland. Surgical intervention is associated with a reduction in cardiovascular mortality. We report a case of a 56-year-old man with ESRD who developed SHPTH and underwent TPTH+AT of parathyroid tissue into the right brachioradialis muscle. Over the course of 7 years he developed a mass at the site of the autotransplanted gland as well as recurrent refractory hyperparathyroidism with increased forearm uptake noted on sestamibi scan. After excision of this mass, pathology demonstrated hyperplasia of the minced gland fragments which were embedded within a mass of fibroadipose tissue rather than the muscle tissue it was originally transplanted in.

• 대한핵의학회지
• /
• 제29권3호
• /
• pp.319-327
• /
• 1995

목적 : 악성 갈색세포종 및 갑상선수질암의 치료에서 $^{131}I-MIBG$의 유용성에 대하여 분석하고자 한다. 방법 : 1993년 2월부터 1995년 2월까지 원자력병원에서 $^{131}I-MIBG$를 이용하여 치료한 악성 갈색세포종 3예, 갑상선수질암 6예(1예은 다발성 내분비선종 제IIb 형)에 대한 의무기록을 후향적으로 분석하였다. 결과 : 악성 갈색세포종 3예중 수술후 미소전이 병소에 대해 치료한 1예는 19개월간 무병기간을 유지하고 있으며, 수술후 재발한 1예는 불변, 절제가 불가능한 1예는 진행하였다. 갑상선수질암 6예중 평가 가능한 경우는 5예였으며, 완전관해가 2예, 그 중 1예는 완전관해후 9개월에 재발, 불변이지만 증상의 호전이 1예, 진행이 2예였다. 진행되는 환자의 특징은 진단시에 절제불능이거나 수술후 종양이 남아있는 경우로 보였다. 결론 : $^{131}I-MIBG$ 치료는 수술후 미소전이 병소의 치료와 수술후 재발 혹은 전이성 갈색세포종 및 갑상선수질암에서 일부 효과가 있어 다른 선택 가능한 치료방법이 없을 경우 시도해 볼만한 치료방법으로서 향후 충분한 임상례를 통하여 연구되어야 할 것으로 생각된다.

• 대한핵의학회지
• /
• 제14권2호
• /
• pp.41-44
• /
• 1980

To evaluate the change of serum myoglobin in the thyroid disease, we measured serum myoglobin by radioimmunoassay in 24 normal subjects, 34 patients with hyperthyroidism (20 untreated, 14 treated) and 5 patients with hypothyroidism. The mean values of serum myoglobin in 24 normal control, 20 untreated hyperthyroidism, and 14 treated hyperthyroidism were $50.9{\pm}17.0ng/ml,\;39.1{\pm}20.3ng/ml\;and\;51.0{\pm}18.3ng/ml$ respectively. The serum myoglobin level of untreated hyperthyroidism seemed to be lower than that of normal control without statistical significance. The serum myoglobin levels in 5 patients with hypothyroidism ranged 28-156 ng/ml, and 3 patients showed increased serum myoglobin level. We observed one case with severe degree of thyrotoxic myopathy whose serum myoglobin level was markedly elevated initially and was decreased to normal range after treatment. This results suggests that the determination of serum myoglobin might be useful in the evaluation of thyrotoxic myopathy.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권5호
• /
• pp.2369-2374
• /
• 2014

Background and Aim: Selumetinib is a promising and interesting targeted therapy agent as it may reverse radioiodine uptake in patients with radioiodine-refractory differentiated thyroid cancer. We conduct this metaanalysis to compare the efficacy and safety of selumetinib with current therapies in patients with advanced cancer. Methods: An electronic search was conducted using PubMed/ Medicine, EMBASE and Cochrane library databases. Statistical analyses were carried out using either random-effects or fixed-effects models according to the heterogeneity of eligible studies. Results: Six eligible trials involved 601 patients were identified. Compared with current therapies, treatment schedules with selumetinib did not improve progression free survival (hazard ratio, 0.91; 95%CI 0.70-1.17, P= 0.448), but did identify better clinical benefits (odds ratio, 1.24; 95%CI 0.69-2.24, P = 0.472) and less disease progression (hazard ratio, 0.72; 95%CI 0.51-1.00, P = 0.052) though its impact was not statistically significant. Sub-group analysis resulted in significantly improved progression free survival (hazard ratio, 0.61; 95%CI 0.49-0.57, P = 0.00), clinical benefits (odds ratio, 3.04; 95%CI 1.60-5.77, P = 0.001) and reduced disease progression (hazard ratio, 0.35; 95%CI 0.18-0.67, P = 0.001) in patients administrated selumetinib. Dermatitis acneiform (risk ratio, 9.775; 95%CI 3.143-30.395, P = 0.00) and peripheral edema (risk ratio, 2.371; 95%CI 1.690-3.327, P = 0.00) are the most frequently observed adverse effects associated with selumetinib. Conclusions: Compared with current chemotherapy, selumetinib has modest clinical activity as monotherapy in patients with advanced cancer, but combinations of selumetinib with cytotoxic agents in patients with BRAF or KRAS mutations hold great promise for cancer treatment. Dermatitis acneiform and peripheral edema are the most frequently observed adverse effects in patients with selumetinib.